Background Omalizumab is effective and safe in severe allergic asthma. Few data are
available about its impact on lung function and on asthma comorbidities, long-term follow-up …

The Portuguese Severe Asthma Registry (Registo de Asma Grave Portugal, RAG) was
developed by an open collaborative network of asthma specialists. RAG collects data from …

Summary Background. Il Registro italiano dell'Asma Severa (IRSA) è il più recente e più
vasto registro in Italia. Obbiettivo. Migliorare la conoscenza sulle caratteristiche cliniche e …

ABSTRACT Background: Severe asthma affects 5–10% of the 350 million people with
asthma worldwide. Findings from the authors' previous meta-analysis supported …

Severe asthma is a heterogeneous syndrome with several clinical variants and often
represents a complex disease requiring a specialized and multidisciplinary approach, as …

The analysis of outcomes from patients with severe asthma treated with omalizumab, using
real-life prospective data, should contribute to future informed decisions about this treatment …

Asthma is a heterogeneous disease characterized by chronic airway inflammation that
results in a wide spectrum of clinical manifestations. Patients with severe asthma represent a …

Background We designed the PROXIMA study (Patient-Reported Outcomes and Xolair® In
the Management of Asthma) to determine the proportion of patients with severe asthma …

Omalizumab is recommended as an add-on therapy in patients aged≥ 6 years with
inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and …

Objective To assess socio-sanitary expenditure after the addition of omalizumab to standard
treatment in the control of severe asthma and to analyse its effectiveness under standard …